Approved Wire coverage, newest first. Market moves and thesis evidence remain separate.
Uber shares fell after forward bookings guidance came in below expectations, overshadowing the quarter's headline results. CEO Dara Khosrowshahi is leaning on robotaxi partnerships as the next growth lever, setting up a debate over near-term deceleration versus long-term platform optionality.
Eli Lilly reported revenue up 48% year-over-year, powered by surging demand for GLP-1 drugs Mounjaro and Zepbound. The results beat expectations, reinforcing Lilly's position as a dominant force in the diabetes/obesity drug category.
CVS beat on Q2 earnings but shares slid after management flagged a cautious 2027 outlook, overshadowing the near-term print. FY revenue of $402.1B (+7.8% YoY) shows top-line growth intact, but net margin remains razor-thin at 0.4%, keeping the market focused on forward earnings power rather than the beat.
Cencora's Q3 fiscal 2026 slides point to continued specialty pharmaceutical strength and management raised full-year guidance. The print reinforces the low-margin, high-volume distribution model where top-line growth ($321.3B revenue, +9.3% YoY) matters less than incremental specialty mix and cost discipline holding through year-end.
AMD shares fell after its latest earnings as analysts flagged muted upside, a softer margin outlook, and results that couldn't clear elevated expectations. The stock's post-print drop despite continued growth highlights how priced-for-perfection semis names get punished on any hint of deceleration.
Booking Holdings posted profit that beat estimates but flagged Middle East geopolitical risk as a drag on its forward outlook. The stock's reaction will hinge on how much the guidance caution offsets the earnings beat.
Wynn Resorts topped quarterly estimates on strength in its Macau operations and disclosed an opening date for its long-awaited UAE casino resort. The UAE launch introduces a new growth vector beyond the mature Macau/Vegas base, giving investors a fresh catalyst to underwrite forward multiples.
Novo Nordisk reported Q2 2026 adjusted operating profit of DKK 33,389 million and raised its full-year outlook. The guidance hike signals management sees continued strength in GLP-1 demand outpacing prior expectations, a key data point after a stretch of intensified competition from Eli Lilly and pricing pressure narratives.
Spotify missed earnings by €0.15 per share and revenue also came in below estimates, snapping the company's recent run of beats. The miss raises questions about whether Spotify's premium pricing and margin-expansion story is decelerating just as investors had priced in continued outperformance.
Zebra Technologies posted record Q2 2026 results and raised its full-year outlook, citing AI-driven demand momentum. The beat-and-raise sets up a test of whether the stock's reaction can hold through the next quarter as investors assess durability of the AI-linked demand cycle.
Caterpillar shares jumped 9% after the company reported record quarterly revenue, with FY figures showing $67.6B in revenue (+4.3% YoY) and 13.1% net margin on $18.81 diluted EPS. The move suggests demand strength in construction, mining, and energy equipment is holding up better than feared, resetting the bar for how the market prices cyclical industrials into the back half of the year.
Palantir shares jumped after the company reported strong quarterly results, with broader futures also lifted by a Trump-driven market rally. The setup now shifts to whether Palantir's re-rated valuation can hold as investors look ahead to SpaceX-related catalysts and the next print.
Grainger shares fell after the company beat earnings but reported gross margin compression alongside news of its CFO's resignation.
Palantir posted second-quarter results with US sales climbing 23% and management forecasting greater demand from US commercial and government groups for its AI software. The company's FY2025 filings show revenue of $4.5B (+56.2% YoY), 82.4% gross margin, and $0.63 diluted EPS, underscoring the scale of its current growth trajectory.